Insulin Lispro
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Insulin lispro is an FDA-approved rapid-acting insulin peptide/protein hormone analog used for mealtime and correction glycemic control in diabetes. This app supports FDA-approved prescription insulin lispro products only, such as Humalog, Admelog, and Lyumjev when selected by the prescriber; non-prescribed, compounded, research-use, or product-substitution use is unsupported.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Insulin lispro is an FDA-approved rapid-acting insulin peptide/protein hormone analog used for mealtime and correction glycemic control in diabetes. NutriStack rates the supporting evidence as strong. Common adult dosing is Individualized prescription dosing only; meal dose, correction dose, pump settings, and product switching must be set by the diabetes prescriber using glucose monitoring and clinical context., though a prescriber sets the actual dose. This profile indexes 14 sources.
The bottom line
Evidence rating strong. Most-documented uses: rapid onset allows injection at mealtime (within 15 minutes of eating), better postprandial glucose control vs regular insulin, shorter duration reduces risk of late postprandial hypoglycemia. 14 sources indexed (1997–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
A recombinant insulin analogue where the amino acids proline and lysine at positions B28 and B29 are reversed compared to native insulin. This modification reduces self-association and accelerates absorption from the subcutaneous depot. Once absorbed, it acts identically to endogenous insulin, binding insulin receptors, activating the PI3K-Akt signaling cascade, promoting GLUT4 translocation, and facilitating cellular glucose uptake.1,2
Dosing & protocol.
Humalog and Admelog are generally administered within 15 minutes before or immediately after a meal as prescribed; Lyumjev is administered at the start of a meal or within 20 minutes after starting. Rotate sites, verify product and strength, and maintain a backup plan for pump failure.
Full safety detail.
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
2- 1Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetesSource linkedPMIDBrunelle BL, Llewelyn J, Anderson JH Jr et al. · Diabetes care · 1998
Brunelle BL, Llewelyn J, Anderson JH Jr et al.. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes care. 1998
- 2Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysisSource linkedPMIDDavey P, Grainger D, MacMillan J et al. · Clinical therapeutics · 1997
Davey P, Grainger D, MacMillan J et al.. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis. Clinical therapeutics. 1997
Randomized controlled trials
2- 3Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase studySource linkedPMIDKazda C, Leohr J, Liu R et al. · Diabetes, obesity & metabolism · 2022
Kazda C, Leohr J, Liu R et al.. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study. Diabetes, obesity & metabolism. 2022
- 4Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase studySource linkedPMIDLeohr J, Kazda C, Liu R et al. · Diabetes, obesity & metabolism · 2022
Leohr J, Kazda C, Liu R et al.. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study. Diabetes, obesity & metabolism. 2022
Reviews & position papers
1- 5Effectiveness and safety of Humalog Mix 50/50 versus Humalog Mix 75/25 in Chinese patients with type 2 diabetesSource linkedPMIDZafar MI, Ai X, Shafqat RA et al. · Therapeutics and clinical risk management · 2015
Zafar MI, Ai X, Shafqat RA et al.. Effectiveness and safety of Humalog Mix 50/50 versus Humalog Mix 75/25 in Chinese patients with type 2 diabetes. Therapeutics and clinical risk management. 2015
Reference material
9- 6HUMALOG (insulin lispro) injection, solution: prescribing informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026
Label includes hypoglycemia and hypersensitivity contraindications plus warnings for pen/cartridge sharing, regimen changes, medication errors, U-200 syringe transfer, hypoglycemia, hypokalemia, hypersensitivity, TZD-related heart failure, and pregnancy risk language.
- 7ADMELOG (insulin lispro) injection, solution: prescribing informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026
Label covers rapid-acting U-100 insulin lispro administration around meals, pump use, contraindications, medication errors, hypoglycemia, hypokalemia, pen/syringe sharing, and pregnancy risk language.
- 8LYUMJEV (insulin lispro-aabc) injection, solution: prescribing informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026
Label covers insulin lispro-aabc administration at the start of a meal or within 20 minutes after starting, pump safety, U-200 syringe-transfer warning, hypoglycemia, hypokalemia, and pregnancy risk language.
- 9FDA Insulin safety informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026
FDA advises not sharing insulin needles, pens, or cartridges and emphasizes using the correct insulin type and device.
- 10Anderson JH Jr et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157(11):1249-1255.Source linkedPMID
- 11Heller SR et al. Insulin lispro: a useful advance in insulin therapy. Expert Opin Pharmacother. 2004;5(4):917-933.Source linkedPMID
- 12Rakab MS et al. Ultra-rapid lispro or fast-acting aspart compared to standard insulin lispro and aspart using closed-loop insulin therapy: a systematic review and meta-analysis of randomized control trials. Front Endocrinol (Lausanne). 2025.Source linkedPMID
- 13Rosenstock J, Frías JP, Rodbard HW et al.. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023Source linkedPMID
- 14Muzaffer Z, Iqbal A, Ristic S. Insulin lispro--a review. JPMA. The Journal of the Pakistan Medical Association. 1998Source linkedPMID
Common questions.
Quick answers about Insulin Lispro, drawn from the data on this page.
What is Insulin Lispro?
Insulin lispro is an FDA-approved rapid-acting insulin peptide/protein hormone analog used for mealtime and correction glycemic control in diabetes. This app supports FDA-approved prescription insulin lispro products only, such as Humalog, Admelog, and Lyumjev when selected by the prescriber; non-prescribed, compounded, research-use, or product-substitution use is unsupported.
What is Insulin Lispro used for?
Commonly cited benefits of Insulin Lispro include: Rapid onset allows injection at mealtime (within 15 minutes of eating); Better postprandial glucose control vs regular insulin; Shorter duration reduces risk of late postprandial hypoglycemia; Flexible timing around meals; Compatible with insulin pump therapy. NutriStack rates the overall evidence as strong.
What is a typical dose of Insulin Lispro?
A typical adult dose of Insulin Lispro is Individualized prescription dosing only; meal dose, correction dose, pump settings, and product switching must be set by the diabetes prescriber using glucose monitoring and clinical context.. The commonly recommended form is FDA-approved prescription rapid-acting insulin lispro product selected by the prescriber. Do not substitute U-100/U-200 products, pens, vials, cartridges, or pump use without prescriber/pharmacist direction.. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Insulin Lispro?
Reported side effects include hypoglycemia, weight gain, injection site reactions (lipodystrophy, redness), hypokalemia, allergic reactions (rare), peripheral edema. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Insulin Lispro?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Insulin Lispro in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.